PRESS RELEASE: Melbourne, December 1, 2014 – Australia’s largest clinical trial is a step closer to revealing in 2018 whether healthy older people should or should not take aspirin to prevent or delay cardiovascular disease (heart attack and stroke), dementia, depression and some types of cancers. ASPREE (ASPirin in Reducing Events in the Elderly), a…
Details
PRESS RELEASE: Melbourne, 20 October 2014: The use of aspirin to prevent cancer will be discussed by experts at a symposium in Melbourne today. Leading healthcare professionals will discuss the scientific evidence for and against the use of aspirin for the chemoprevention of cancer. With the rising importance of disease prevention, researchers are looking at…
Details
The Principal Investigator for the Australian arm of the ASPREE study, Professor John McNeil (pictured left), urges that reports on the benefits or the risks of daily aspirin in healthy people should be taken in context. “Most major health organisations will not ‘jump the gun’ and recommend aspirin to healthy people without evidence. They are not making…
Details
Government and health authorities make recommendations based on scientific evidence that proves the benefit of a particular therapy outweighs the risks. All medications have side effects and low-dose aspirin is no exception. Aspirin is often prescribed for secondary prevention in people who have had a heart attack or stroke because research demonstrates that in this…
DetailsThe US Food and Drug Administration’s (FDA) decision not to recommend aspirin for primary prevention due to a lack of scientific evidence, adds further support for the ASPREE study. In a statement issued on their website, the FDA reported that the potential benefits of aspirin had not yet been established against known risks, such as…
Details
Senior researchers in the ASPREE (ASPirin in Reducing Events in the Elderly) trial were in Shepparton this week to give the first of several study updates planned for Australian participants this year. Executive Officer of ASPREE, Associate Professor Robyn Woods, presented an update on the aspirin study’s progress at a morning tea for participants living in…
Details
The ASPREE study does not have preliminary findings at this point in time – the trial is still in the recruitment phase and will continue to be so until mid 2014. If you have further questions, please ring 1800 728 745 (toll free from a landline).
PRESS RELEASE Wollongong locals to participate in Australia’s largest primary prevention Aspirin Trial Wollongong, October 3, 2013 – The ASPREE (ASPirin in Reducing Events in the Elderly) study – the largest primary prevention aspirin study ever undertaken in older people – is calling on local residents from Wollongong and surrounding regions to participate in the study.…
Details
The ASPREE (ASPirin in Reducing Events in the Elderly) study hosted a study update and morning tea at the Windsor Community Precinct on Friday 8th March to celebrate reaching 400 participants in the Launceston region. Special guest and Tamar Valley resident Peter Cundall – renowned horticulturalist and former host of the ABC program Gardening Australia –…
Details
World-first Aspirin study reaches new milestone – 10,000 participants PRESS RELEASE: Melbourne, February 21 2013 – The largest primary prevention aspirin study ever undertaken in older people has reached an important milestone, signing up 10,000 participants in Australia. The landmark ASPREE (ASPirin in Reducing Events in the Elderly) study is investigating whether a daily low…
Details© 2019 All Rights Reserved. • Monash University, Department of Epidemiology and Preventive Medicine | Disclaimer & Privacy